Jay Kailash Namkeen approves ₹15.25 crore preferential issue at 5th AGM
- Jay Kailash Namkeen approved a preferential issue of 33.74 lakh shares totaling ₹15.25 crore
- Four new independent directors joined the board alongside three other director appointments
- Neel Narendrabhai Pujara was re-appointed as director by rotation
- MRB & Associates appointed as statutory auditors for five years
- Financial statements for FY26 were adopted at the Rajkot-based meeting

*this image is generated using AI for illustrative purposes only.
Jay Kailash Namkeen concluded its fifth annual general meeting on September 12, 2026. Shareholders approved a significant expansion of the board and authorized a preferential equity issuance valued at ₹15.25 crore.
The meeting, chaired by Managing Director Neel Narendrabhai Pujara, took place at RPJ Hotel in Rajkot. Members utilized remote e-voting facilities available from September 9 to September 11, with polling paper voting conducted for attendees who had not cast votes electronically.
Board Appointments
The company significantly expanded its board composition during the meeting. Shareholders approved the appointment of three new directors:
- Chirag Jayeshbhai Archlani
- Aadi N Kalavadia
- Sanjay Chandrakant Rao as Non-Executive Director
Additionally, four individuals were appointed as Independent Directors through special resolutions:
- Pooja Jamnabhai Varsani
- Dipakbhai Bhikhubhai Hariyani
- Vipin Vishvanath Agrawal
- Satnam Singh Chandok
Neel Narendrabhai Pujara was re-appointed as a director by rotation. The meeting also approved the sitting fees payable to the newly appointed independent directors.
Preferential Equity Issue
A key financial outcome of the AGM was the approval of a preferential allotment of equity shares. The company is authorized to issue up to 33,74,375 equity shares of face value ₹10 each.
| Parameter | Details |
|---|---|
| Number of Shares | 33,74,375 |
| Face Value | ₹10 |
| Issue Price | ₹45.19 |
| Premium | ₹35.19 per share |
| Total Proceeds | ₹15,24,88,006 |
The shares are being issued on a preferential basis to proposed allottees for consideration other than cash. This transaction represents a capital infusion of approximately ₹15.25 crore into the company.
Other Business
M/s. MRB & Associates, Chartered Accountants, were appointed as Statutory Auditors for a term of five consecutive years. The audited standalone financial statements for the fiscal year ended March 31, 2026, were considered and adopted during the proceedings.
The meeting concluded at 12:30 pm after all business items were transacted. M/s. Mamta Binani and Associates served as the scrutinizer for the voting process.
Historical Stock Returns for Jay Kailash Namkeen
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.21% | -2.64% | +46.32% | +318.01% | +17.74% | 0.0% |
Who are the specific entities or promoters receiving the preferential allotment, and what strategic assets or synergies are they contributing in exchange for equity?
How will the infusion of ₹15.25 crore be allocated across Jay Kailash Namkeen's expansion plans, such as capacity augmentation, new product launches, or market penetration?
What specific expertise do the newly appointed independent directors bring to the board, and how might their governance influence the company's strategic direction?

































